Chinook Therapeutics Inc
NASDAQ:KDNY
| Market Cap (Intraday) | 1.46B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $25.11 |
| 50-Day MA | $24.58 |
| 200-Day MA | $20.25 |
Chinook Therapeutics Inc Stock, NASDAQ:KDNY
400 Fairview Avenue North, Suite 900, Seattle, Washington 98109
United States of America
Phone: +1.206.485.7241
Number of Employees: 138
Description
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA.